You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

39 search results for: disease background

The Burden of Atopic Dermatitis in Children – The Impact of Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

1 min

Dermatology

Dr. Mark Koh explains how age at disease onset is linked to persistent disease.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

How do You Define Active <b>Disease</b> (CRSwNP) When Looking at the Nose With an Endoscope?

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics

Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

5 min

Dermatology

An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

ADVENT On Air | Exploring PN as a Distinct and Unique <b>Disease</b>

Podcast

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min

Dermatology

Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.

Why targeting Type 2 Inflammation is important in the treatment of skin <b>disease</b>s like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

Atopic Dermatitis (AD) is a Type 2 Inflammatory <b>Disease</b>

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

2 min

Dermatology

Discover the pathophysiological mechanisms involved in atopic dermatitis.

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

expert video

Unmet Needs in Bullous Pemphigoid

3 min

Dermatology

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.

expert video

Pathophysiology of Bullous Pemphigoid

4 min

Dermatology

Join Dr. Schmidt as he describes the pathophysiology of bullous pemphigoid, as well as novel research avenues to better understand this complicated disease.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region